AG-CN2-0460-M0055 mgCHF 80.00
AG-CN2-0460-M01010 mgCHF 145.00
AG-CN2-0460-M05050 mgCHF 580.00
|Synonyms||Tripterine; NSC 70931|
|Merck Index||14: 10370|
|Source/Host Chemicals||Isolated from Tripterygium wilfordii.|
|Purity Chemicals||≥98% (HPLC)|
|Solubility||Soluble in DMSO, ethanol or dimethylformamide. Insoluble in water.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Protect from light.
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Anti-obesity agent. Potent leptin sensitizer.
- Potent lipid peroxidation inhibitor.
- NADPH oxidases (NOX1, 2, 4 and 5) inhibitor.
- Anti-inflammatory. NF-κB inhibitor.
- HSP90 inhibitor and HSP70 inducer.
- Anticancer agent. Apoptosis and autophagy inducer. Inhibits PI3K/Akt signaling pathways.
- Anti-metastatic and anti-angiogenic compound. Reduces VEGFR expression and inhibits HIF-1α pathway.
- Topoisomerase II inhibitor.
- 20S proteasome chymotrypsin-like activity inhibitor.
- Potential antiviral and anti-Alzheimer's agent.
- The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria: H. Sassa, et al.; BBRC 172, 890 (1990)
- Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease: A.C. Allison, et al.; Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 1341 (2001)
- Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production: H.Z. Jin, et al.; J. Nat. Prod. 65, 89 (2002)
- Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol: M. Nagase, et al.; Biosci. Biotechnol. Biochem. 67, 1883 (2003)
- Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid: J.H. Lee, et al.; Biochem. Pharmacol. 72, 1311 (2006)
- Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice: H. Yang, et al.; Cancer Res. 66, 4758 (2006)
- Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation: Z. Lu, et al.; Cancer Lett. 290, 182 (2010)
- Celastrol: Molecular targets of Thunder God Vine: A. Salminen, et al.; BBRC 394, 439 (2010) (Review)
- Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway: H. Zhu, et al.; J. Pharmacol. Exp. Ther. 334, 489 (2010)
- Inhibitory action of Celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1α pathway: L. Huang, et al.; Int. J. Mol. Med. 27, 407 (2011)
- NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action: V. Jaquet, et al.; Br. J. Pharmacol. 164, 507 (2011)
- Celastrol inhibits Tat-mediated human immunodeficiency virus (HIV) transcription and replication: V. Narayan, et al.; J. Mol. Biol. 410, 972 (2011)
- Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways: R. Kannaiyan, et al.; Apoptosis 16, 1028 (2011)
- Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice: J.E. Kim, et al.; PLoS One 8, e62068 (2013)
- Inhibition of C2C12 myotube atrophy by a novel HSP70 inducer, celastrol, via activation of Akt1 and ERK1/2 pathways: T. Gwag, et al.; Arch. Biochem. Biophys. 537, 21 (2013)
- Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study: H.Y. Li, et al.; Cell Death Dis. 6, e1604 (2015)
- Treatment of obesity with celastrol: J. Liu, et al.; Cell 161, 999 (2015)